output stringlengths 5 24.3k | instruction stringlengths 33 308 | system stringclasses 1 value |
|---|---|---|
1. Anti-Inflammatory Agents, Non-Steroidal [adverse effects]; 2. *Breast Neoplasms [surgery]; 3. Ketorolac [therapeutic use]; 4. Pain, Postoperative [drug therapy]; 5. *Pharmaceutical Preparations; | Provide MESH terms for the study
Perioperative systemic nonsteroidal anti‐inflammatory drugs (NSAIDs) in women undergoing breast surgery | You are a research assistant. Based on the question please provide appropriate answers |
1. Anxiety; 2. *Music; 3. *Music Therapy; 4. *Neoplasms [therapy]; 5. Quality of Life; | Provide MESH terms for the study
Music interventions for improving psychological and physical outcomes in people with cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Anticoagulants [adverse effects]; 2. Heparin; 3. Heparin, Low-Molecular-Weight; 4. *Neoplasms [complications, drug therapy]; 5. Systematic Reviews as Topic; 6. *Venous Thromboembolism [prevention & control]; | Provide MESH terms for the study
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation | You are a research assistant. Based on the question please provide appropriate answers |
1. Anti-Bacterial Agents [therapeutic use]; 2. *Catheter-Related Infections [prevention & control]; 3. *Central Venous Catheters [adverse effects]; 4. Heparin; 5. *Neoplasms [complications, drug therapy]; | Provide MESH terms for the study
Prophylactic antibiotics for preventing gram‐positive infections associated with long‐term central venous catheters in adults and children receiving treatment for cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Anticoagulants [adverse effects]; 2. *Fibrinolytic Agents; 3. Heparin; 4. Heparin, Low-Molecular-Weight; 5. *Multiple Myeloma [drug therapy]; | Provide MESH terms for the study
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents | You are a research assistant. Based on the question please provide appropriate answers |
1. *Exercise; 2. Physical Fitness; 3. *Quality of Life; 4. Randomized Controlled Trials as Topic; 5. Schools; 6. Sedentary Behavior; | Provide MESH terms for the study
School‐based physical activity programs for promoting physical activity and fitness in children and adolescents aged 6 to 18 | You are a research assistant. Based on the question please provide appropriate answers |
1. Anastomosis, Roux-en-Y [adverse effects]; 2. Gastrectomy [adverse effects]; 3. Postoperative Complications; 4. Randomized Controlled Trials as Topic; 5. *Stomach Neoplasms [surgery]; | Provide MESH terms for the study
Roux‐en‐Y versus Billroth‐I reconstruction after distal gastrectomy for gastric cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Bile Duct Neoplasms [drug therapy, surgery]; 2. Bile Ducts, Intrahepatic; 3. Chemotherapy, Adjuvant; 4. *Cholangiocarcinoma [drug therapy, surgery]; 5. Neoplasm Recurrence, Local; 6. Quality of Life; | Provide MESH terms for the study
Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma | You are a research assistant. Based on the question please provide appropriate answers |
1. Bias; 2. Mass Screening; 3. *Uterine Cervical Neoplasms [diagnosis, prevention & control]; 4. Vaccination; | Provide MESH terms for the study
Interventions targeted at women to encourage the uptake of cervical screening | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; 2. *Hematopoietic Stem Cell Transplantation; 3. Progression-Free Survival; 4. *Sarcoma, Ewing [drug therapy]; 5. Transplantation, Autologous; | Provide MESH terms for the study
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma | You are a research assistant. Based on the question please provide appropriate answers |
1. *Breast Neoplasms [radiotherapy, surgery]; 2. *Carcinoma, Intraductal, Noninfiltrating; 3. Mastectomy; 4. Mastectomy, Segmental; 5. Radiation Dose Hypofractionation; | Provide MESH terms for the study
Partial breast irradiation versus whole breast radiotherapy for early breast cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Analgesics, Opioid [adverse effects]; 2. *Cancer Pain [drug therapy]; 3. Hydromorphone [adverse effects]; 4. Morphine [adverse effects]; 5. *Neoplasms [complications]; 6. Oxycodone; | Provide MESH terms for the study
Hydromorphone for cancer pain | You are a research assistant. Based on the question please provide appropriate answers |
1. Disease Progression; 2. Hormones; 3. Oligopeptides; 4. *Prostatic Neoplasms [drug therapy]; 5. *Quality of Life; | Provide MESH terms for the study
Degarelix for treating advanced hormone‐sensitive prostate cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Exercise; 2. Exercise Therapy; 3. *Neoplasms [therapy]; 4. Physical Fitness; 5. Physical Therapy Modalities; 6. Quality of Life; | Provide MESH terms for the study
Physical therapy interventions, other than general physical exercise interventions, in children and adolescents before, during and following treatment for cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Agents [*therapeutic use]; 2. Bias; 3. *Carcinoma, Ovarian Epithelial [drug therapy, mortality, pathology, surgery]; 4. Chemotherapy, Adjuvant [methods, mortality]; 5. Cytoreduction Surgical Procedures [adverse effects, *methods, mortality]; 6. Neoadjuvant Therapy [*methods]; 7. *Ovarian Neoplasms [drug therapy, mortality, pathology, surgery]; 8. Postoperative Complications [epidemiology, etiology]; 9. Preoperative Care; 10. Progression-Free Survival; 11. Randomized Controlled Trials as Topic; 12. Treatment Outcome; | Provide MESH terms for the study
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Bias; 2. Bone Neoplasms [mortality, *radiotherapy]; 3. Chordoma [mortality, *radiotherapy]; 4. Disease-Free Survival; 5. Neoplasm Recurrence, Local [prevention & control]; 6. Observational Studies as Topic; 7. Photons [adverse effects, *therapeutic use]; 8. Progression-Free Survival; 9. Proton Therapy [adverse effects, *methods]; 10. Radiosurgery [methods]; 11. Radiotherapy, Adjuvant; 12. Radiotherapy, Intensity-Modulated [methods]; 13. Time Factors; | Provide MESH terms for the study
Protons versus photons for the treatment of chordoma | You are a research assistant. Based on the question please provide appropriate answers |
1. Adjuvants, Immunologic [administration & dosage]; 2. Administration, Intravesical; 3. Antibiotics, Antineoplastic [administration & dosage, adverse effects]; 4. Antimetabolites, Antineoplastic [*administration & dosage, adverse effects]; 5. BCG Vaccine [administration & dosage]; 6. Bias; 7. Cause of Death; 8. Confidence Intervals; 9. Deoxycytidine [administration & dosage, adverse effects, *analogs & derivatives]; 10. Disease Progression; 11. Drug Administration Schedule; 12. Gemcitabine; 13. Mitomycin [administration & dosage, adverse effects]; 14. Neoplasm Recurrence, Local [*drug therapy, mortality, prevention & control]; 15. Randomized Controlled Trials as Topic; 16. Saline Solution [administration & dosage]; 17. Urinary Bladder Neoplasms [*drug therapy, mortality, pathology, prevention & control]; | Provide MESH terms for the study
Intravesical gemcitabine for non‐muscle invasive bladder cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Antibodies, Monoclonal [therapeutic use]; 2. Antibodies, Monoclonal, Humanized [therapeutic use]; 3. Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; 4. B7-H1 Antigen [metabolism]; 5. Bevacizumab [adverse effects, *therapeutic use]; 6. Bias; 7. Carcinoma, Non-Small-Cell Lung [*drug therapy, metabolism, mortality, pathology]; 8. Immune Checkpoint Inhibitors [adverse effects, *therapeutic use]; 9. Lung Neoplasms [*drug therapy, mortality, pathology]; 10. Nivolumab [adverse effects, therapeutic use]; 11. Platinum Compounds [adverse effects, therapeutic use]; 12. Progression-Free Survival; 13. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Bias; 2. Breast Neoplasms [chemistry, *drug therapy, genetics, pathology]; 3. Genes, BRCA1; 4. Genes, BRCA2; 5. Germ-Line Mutation; 6. Poly(ADP-ribose) Polymerase Inhibitors [adverse effects, *therapeutic use]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Triple Negative Breast Neoplasms [drug therapy, genetics, pathology]; | Provide MESH terms for the study
PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Afatinib [adverse effects, therapeutic use]; 2. Antineoplastic Agents [adverse effects, *therapeutic use]; 3. Antineoplastic Combined Chemotherapy Protocols [therapeutic use]; 4. Bias; 5. Carboplatin [therapeutic use]; 6. Carcinoma, Non-Small-Cell Lung [*drug therapy, genetics, mortality]; 7. Cetuximab [adverse effects, therapeutic use]; 8. Crown Ethers [adverse effects, therapeutic use]; 9. ErbB Receptors [*genetics]; 10. Erlotinib Hydrochloride [adverse effects, therapeutic use]; 11. Gefitinib [adverse effects, therapeutic use]; 12. Lung Neoplasms [*drug therapy, genetics, mortality]; 13. *Mutation; 14. Paclitaxel [therapeutic use]; 15. Pemetrexed [therapeutic use]; 16. Progression-Free Survival; 17. Protein Kinase Inhibitors [adverse effects, therapeutic use]; 18. Quality of Life; 19. Quinazolines [adverse effects, therapeutic use]; 20. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Bias; 2. Cachexia [etiology, *therapy]; 3. Combined Modality Therapy [methods]; 4. *Exercise; 5. Exercise Tolerance; 6. Fatigue [etiology]; 7. Head and Neck Neoplasms [complications]; 8. Lung Neoplasms [complications]; 9. Muscle Strength; 10. Neoplasms [*complications]; 11. Pancreatic Neoplasms [complications]; 12. Patient Compliance; 13. Physical Endurance; 14. Quality of Life; 15. Randomized Controlled Trials as Topic; 16. Thinness; | Provide MESH terms for the study
Exercise for cancer cachexia in adults | You are a research assistant. Based on the question please provide appropriate answers |
1. Angiogenesis Inhibitors [adverse effects, *therapeutic use]; 2. Antineoplastic Agents [adverse effects, *therapeutic use]; 3. Bevacizumab [adverse effects, therapeutic use]; 4. Bias; 5. Brachytherapy [adverse effects]; 6. Combined Modality Therapy [adverse effects, methods]; 7. Confidence Intervals; 8. Gastric Fistula [chemically induced]; 9. Gastrointestinal Hemorrhage [chemically induced]; 10. Hypertension [chemically induced]; 11. Indazoles; 12. Intestinal Fistula [chemically induced]; 13. Intestinal Perforation [chemically induced]; 14. Lapatinib [adverse effects, therapeutic use]; 15. Neoplasm Recurrence, Local [blood supply, *drug therapy, mortality]; 16. Progression-Free Survival; 17. Pyridines [adverse effects, therapeutic use]; 18. Pyrimidines [adverse effects, therapeutic use]; 19. Quality of Life; 20. Quinazolines [adverse effects, therapeutic use]; 21. Randomized Controlled Trials as Topic; 22. Sulfonamides [adverse effects, therapeutic use]; 23. Thromboembolism [chemically induced]; 24. Uterine Cervical Neoplasms [blood supply, *drug therapy, mortality]; 25. Vascular Endothelial Growth Factor A [*antagonists & inhibitors]; | Provide MESH terms for the study
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Analgesia [*methods]; 2. Anesthesia Recovery Period; 3. Anesthesia, General [*methods]; 4. Anesthesia, Spinal [adverse effects, *methods]; 5. Bias; 6. Breast Neoplasms [immunology, *surgery]; 7. Early Ambulation; 8. Horner Syndrome [epidemiology]; 9. Incidence; 10. Intention to Treat Analysis; 11. Length of Stay; 12. Nerve Block [methods]; 13. Pain Measurement [methods]; 14. Pain, Postoperative [diagnosis, prevention & control]; 15. Patient Satisfaction; 16. Postoperative Nausea and Vomiting [epidemiology, prevention & control]; 17. Randomized Controlled Trials as Topic; 18. Stress, Physiological [*drug effects]; | Provide MESH terms for the study
Paravertebral anaesthesia with or without sedation versus general anaesthesia for women undergoing breast cancer surgery | You are a research assistant. Based on the question please provide appropriate answers |
1. *Brain Neoplasms; 2. *Glioblastoma [therapy]; 3. Lomustine [therapeutic use]; 4. Neoplasm Recurrence, Local [drug therapy]; 5. Network Meta-Analysis; | Provide MESH terms for the study
Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis | You are a research assistant. Based on the question please provide appropriate answers |
1. Adenocarcinoma [chemically induced, prevention & control]; 2. Antineoplastic Agents, Hormonal [adverse effects]; 3. Breast Neoplasms [chemistry, mortality, *prevention & control]; 4. Chemotherapy, Adjuvant; 5. Confidence Intervals; 6. Contraceptive Agents, Female [administration & dosage]; 7. Endometrial Hyperplasia [chemically induced, epidemiology, *prevention & control]; 8. Endometrial Neoplasms [chemically induced, epidemiology, *prevention & control]; 9. *Intrauterine Devices, Medicated; 10. Levonorgestrel [*administration & dosage, adverse effects]; 11. Neoplasm Recurrence, Local [mortality, *prevention & control]; 12. Polyps [chemically induced, epidemiology, prevention & control]; 13. Randomized Controlled Trials as Topic; 14. Tamoxifen [adverse effects]; 15. Uterine Hemorrhage [chemically induced, epidemiology]; 16. Uterus [drug effects]; | Provide MESH terms for the study
Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen | You are a research assistant. Based on the question please provide appropriate answers |
1. Abiraterone Acetate [adverse effects, *therapeutic use]; 2. Androgen Antagonists [adverse effects, *therapeutic use]; 3. Antineoplastic Agents, Hormonal [*therapeutic use]; 4. Disease Progression; 5. Neoplasm Grading; 6. Prostatic Neoplasms [*drug therapy, mortality, pathology]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Withholding Treatment [statistics & numerical data]; | Provide MESH terms for the study
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Body Mass Index; 2. Breast Neoplasms [*complications, epidemiology]; 3. *Cancer Survivors; 4. Combined Modality Therapy [methods]; 5. Exercise; 6. Neoplasm Recurrence, Local [epidemiology]; 7. Obesity [*therapy]; 8. Overweight [*therapy]; 9. Psychotherapy; 10. Quality of Life; 11. Randomized Controlled Trials as Topic; 12. Waist Circumference; 13. *Weight Loss; 14. Weight Reduction Programs; | Provide MESH terms for the study
Body weight management in overweight and obese breast cancer survivors | You are a research assistant. Based on the question please provide appropriate answers |
1. Alendronate [adverse effects, therapeutic use]; 2. Antineoplastic Agents, Hormonal [therapeutic use]; 3. Bisphosphonate-Associated Osteonecrosis of the Jaw [etiology]; 4. Bone Density Conservation Agents [adverse effects, *therapeutic use]; 5. Bone Neoplasms [*drug therapy, *secondary]; 6. Clodronic Acid [adverse effects, therapeutic use]; 7. Denosumab [adverse effects, *therapeutic use]; 8. Diphosphonates [adverse effects, *therapeutic use]; 9. Etidronic Acid [adverse effects, therapeutic use]; 10. Network Meta-Analysis; 11. Pamidronate [adverse effects, therapeutic use]; 12. Prostatic Neoplasms [drug therapy, *pathology]; 13. Prostatic Neoplasms, Castration-Resistant [pathology]; 14. Quality of Life; 15. Randomized Controlled Trials as Topic; 16. RANK Ligand [*antagonists & inhibitors]; 17. Risedronic Acid [adverse effects, therapeutic use]; 18. Zoledronic Acid [adverse effects, therapeutic use]; | Provide MESH terms for the study
Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Agents [adverse effects, *therapeutic use]; 2. Bias; 3. Carboplatin [adverse effects, *therapeutic use]; 4. Cisplatin [adverse effects, *therapeutic use]; 5. Genes, BRCA1; 6. Genes, BRCA2; 7. Nausea [chemically induced]; 8. Oxaliplatin [adverse effects, *therapeutic use]; 9. Progression-Free Survival; 10. Randomized Controlled Trials as Topic; 11. Triple Negative Breast Neoplasms [*drug therapy, genetics, mortality]; 12. Vomiting [chemically induced]; | Provide MESH terms for the study
Platinum‐containing regimens for triple‐negative metastatic breast cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Antibodies, Monoclonal, Humanized [adverse effects, therapeutic use]; 2. Antineoplastic Agents [adverse effects, *therapeutic use]; 3. Antineoplastic Agents, Immunological [therapeutic use]; 4. Axitinib [adverse effects, therapeutic use]; 5. Bevacizumab [adverse effects, therapeutic use]; 6. Bias; 7. Carcinoma, Renal Cell [*drug therapy, mortality]; 8. Everolimus [adverse effects, therapeutic use]; 9. Indazoles; 10. Ipilimumab [adverse effects, therapeutic use]; 11. Kidney Neoplasms [*drug therapy, mortality, pathology]; 12. Phenylurea Compounds [adverse effects, therapeutic use]; 13. Progression-Free Survival; 14. Protein Kinase Inhibitors [adverse effects, *therapeutic use]; 15. Pyrimidines [adverse effects, therapeutic use]; 16. Quality of Life; 17. Quinolines [adverse effects, therapeutic use]; 18. Randomized Controlled Trials as Topic; 19. Receptors, Vascular Endothelial Growth Factor [antagonists & inhibitors]; 20. Sirolimus [adverse effects, analogs & derivatives, therapeutic use]; 21. Sorafenib [adverse effects, therapeutic use]; 22. Sulfonamides [adverse effects, therapeutic use]; 23. Sunitinib [adverse effects, therapeutic use]; | Provide MESH terms for the study
Targeted therapy for metastatic renal cell carcinoma | You are a research assistant. Based on the question please provide appropriate answers |
1. Anticoagulants [adverse effects, *therapeutic use]; 2. Antineoplastic Agents [*adverse effects]; 3. Antithrombins [adverse effects, therapeutic use]; 4. Asparaginase [*adverse effects]; 5. Bias; 6. Cause of Death; 7. Placebos [therapeutic use]; 8. Precursor Cell Lymphoblastic Leukemia-Lymphoma [*drug therapy]; 9. Venous Thromboembolism [chemically induced, mortality, *prevention & control]; | Provide MESH terms for the study
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia | You are a research assistant. Based on the question please provide appropriate answers |
1. Ambulatory Care [economics]; 2. Bias; 3. Caregivers [psychology, *statistics & numerical data]; 4. Cost-Benefit Analysis; 5. Family; 6. Heart Failure [mortality, therapy]; 7. Home Care Services, Hospital-Based [*economics]; 8. Hospitalization [economics]; 9. Neoplasms [mortality, therapy]; 10. Pain Management [statistics & numerical data]; 11. Palliative Care [*economics, *methods]; 12. Patient Satisfaction; 13. Quality of Life; 14. Randomized Controlled Trials as Topic; 15. Symptom Assessment [statistics & numerical data]; 16. Terminal Care [*economics, *methods]; | Provide MESH terms for the study
The effectiveness and cost‐effectiveness of hospital‐based specialist palliative care for adults with advanced illness and their caregivers | You are a research assistant. Based on the question please provide appropriate answers |
1. Kallikreins [blood]; 2. Laparoscopy [adverse effects, methods]; 3. Margins of Excision; 4. Organ Sparing Treatments [adverse effects, *methods]; 5. Penile Erection; 6. Postoperative Complications [epidemiology, *prevention & control]; 7. Prostate-Specific Antigen [blood]; 8. Prostatectomy [adverse effects, *methods]; 9. Prostatic Neoplasms [blood, pathology, *surgery]; 10. Randomized Controlled Trials as Topic; 11. Robotic Surgical Procedures [adverse effects, *methods]; 12. Time Factors; 13. Treatment Outcome; 14. Urinary Incontinence [epidemiology, *prevention & control]; | Provide MESH terms for the study
Retzius‐sparing versus standard robotic‐assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer. | You are a research assistant. Based on the question please provide appropriate answers |
1. Anti-Bacterial Agents [*therapeutic use]; 2. Anti-Ulcer Agents [therapeutic use]; 3. Asymptomatic Infections [*therapy]; 4. Carcinoma, Squamous Cell [epidemiology]; 5. Drug Therapy, Combination [adverse effects, methods]; 6. Esophageal Neoplasms [epidemiology]; 7. Helicobacter Infections [*drug therapy]; 8. *Helicobacter pylori; 9. Incidence; 10. Precancerous Conditions [drug therapy]; 11. Randomized Controlled Trials as Topic; 12. Stomach Neoplasms [microbiology, mortality, *prevention & control]; | Provide MESH terms for the study
Helicobacter pylori eradication for the prevention of gastric neoplasia | You are a research assistant. Based on the question please provide appropriate answers |
1. Cause of Death; 2. Disease Progression; 3. Erectile Dysfunction [epidemiology]; 4. Palliative Care; 5. Postoperative Complications [epidemiology]; 6. Prostatectomy [adverse effects, *methods, mortality]; 7. Prostatic Neoplasms [mortality, pathology, surgery, *therapy]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Urinary Incontinence [epidemiology]; 11. *Watchful Waiting; | Provide MESH terms for the study
Radical prostatectomy versus deferred treatment for localised prostate cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Anxiety [etiology, therapy]; 2. Cancer Pain [therapy]; 3. Depression [etiology, therapy]; 4. Dyspnea [etiology, therapy]; 5. Fatigue [etiology, therapy]; 6. Neoplasms [*complications, psychology, therapy]; 7. Randomized Controlled Trials as Topic; 8. Self Care; 9. Sexual Dysfunction, Physiological [etiology, therapy]; 10. Stress, Psychological [etiology, therapy]; 11. Symptom Assessment; 12. Telemedicine [*methods]; 13. *Telephone [statistics & numerical data]; 14. Time Factors; 15. Uncertainty; | Provide MESH terms for the study
Telephone interventions for symptom management in adults with cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Barrett Esophagus [pathology, *surgery]; 2. Esophageal Neoplasms [pathology, *surgery]; 3. Esophagoscopy [*methods]; 4. Precancerous Conditions [pathology, *surgery]; | Provide MESH terms for the study
Surgery versus radical endotherapies for early cancer and high‐grade dysplasia in Barrett's oesophagus | You are a research assistant. Based on the question please provide appropriate answers |
1. Age Factors; 2. Brain Neoplasms [mortality, pathology, *radiotherapy]; 3. Cranial Irradiation [*methods, mortality]; 4. Disease-Free Survival; 5. *Dose Fractionation, Radiation; 6. Glioma [mortality, pathology, *radiotherapy]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Survival Analysis; | Provide MESH terms for the study
External beam radiation dose escalation for high grade glioma | You are a research assistant. Based on the question please provide appropriate answers |
1. Anxiety [etiology]; 2. Colonic Neoplasms [complications, psychology, therapy]; 3. Colorectal Neoplasms [*complications, psychology, therapy]; 4. Depression [etiology, therapy]; 5. *Exercise; 6. Fatigue [therapy]; 7. *Mental Health; 8. *Physical Fitness; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Time Factors; | Provide MESH terms for the study
Physical activity interventions for disease‐related physical and mental health during and following treatment in people with non‐advanced colorectal cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Network Meta‐Analysis; 2. Bleomycin [therapeutic use]; 3. Doxycycline [therapeutic use]; 4. Dyspnea [therapy]; 5. Fever [etiology]; 6. Iodine [therapeutic use]; 7. Pleural Effusion, Malignant [etiology, mortality, *therapy]; 8. Pleurodesis [*methods, mortality]; 9. Quinacrine [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Talc [therapeutic use]; 12. Treatment Failure; | Provide MESH terms for the study
Interventions for the management of malignant pleural effusions: a network meta‐analysis | You are a research assistant. Based on the question please provide appropriate answers |
1. *Endometrial Neoplasms [diagnosis]; 2. *Health Education [methods]; 3. *Health Knowledge, Attitudes, Practice; 4. *Referral and Consultation; 5. Awareness; 6. Randomized Controlled Trials as Topic; 7. Uterine Hemorrhage [diagnosis, etiology]; | Provide MESH terms for the study
Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Agents, Hormonal [*therapeutic use]; 2. Breast Neoplasms [mortality, *therapy]; 3. Chemotherapy, Adjuvant; 4. Gonadotropin‐Releasing Hormone [*agonists]; 5. Premenopause; 6. Randomized Controlled Trials as Topic; 7. Survival Analysis; 8. Tamoxifen [therapeutic use]; 9. Treatment Outcome; | Provide MESH terms for the study
Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Dietary Supplements; 2. *Health Status; 3. Ascorbic Acid [therapeutic use]; 4. Calcium, Dietary [adverse effects, therapeutic use]; 5. Cholecalciferol [therapeutic use]; 6. Confidence Intervals; 7. Incidence; 8. Lung Neoplasms [epidemiology, mortality, *prevention & control]; 9. Minerals [*therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Selenium; 12. Selenium Compounds [therapeutic use]; 13. Sex Factors; 14. Vitamin A [adverse effects, therapeutic use]; 15. Vitamin E [therapeutic use]; 16. Vitamins [adverse effects, *therapeutic use]; 17. alpha‐Tocopherol [adverse effects, therapeutic use]; 18. beta Carotene [therapeutic use]; | Provide MESH terms for the study
Drugs for preventing lung cancer in healthy people | You are a research assistant. Based on the question please provide appropriate answers |
1. *Exercise Therapy [methods]; 2. Aromatase Inhibitors [*adverse effects, therapeutic use]; 3. Breast Neoplasms [drug therapy]; 4. Musculoskeletal Pain [*chemically induced, *prevention & control]; 5. Neoplasm Staging; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Hormone Replacement Therapy; 2. Carcinoma, Ovarian Epithelial [*drug therapy, surgery]; 3. Menopause, Premature [drug effects]; 4. Ovarian Neoplasms [*drug therapy, surgery]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Hormone replacement therapy after surgery for epithelial ovarian cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Antipsychotic Agents [*therapeutic use]; 2. Chlorpromazine [therapeutic use]; 3. Delirium [*drug therapy, etiology]; 4. Haloperidol [therapeutic use]; 5. Lorazepam [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Terminally Ill [*psychology]; | Provide MESH terms for the study
Drug therapy for delirium in terminally ill adults | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Agents [administration & dosage, *adverse effects]; 2. Carboplatin [administration & dosage, adverse effects]; 3. Cisplatin [administration & dosage, adverse effects]; 4. Disease‐Free Survival; 5. Hearing Loss [*chemically induced]; 6. Organoplatinum Compounds [administration & dosage, *adverse effects]; 7. Oxaliplatin [administration & dosage, adverse effects]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Tinnitus [chemically induced]; | Provide MESH terms for the study
Different infusion durations for preventing platinum‐induced hearing loss in children with cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Brain Neoplasms [mortality, *radiotherapy, surgery]; 2. Disease‐Free Survival; 3. Glioma [*radiotherapy, surgery]; 4. Postoperative Care; 5. Progression‐Free Survival; 6. Radiosurgery; 7. Radiotherapy [methods]; 8. Randomized Controlled Trials as Topic; 9. Time Factors; 10. Watchful Waiting; | Provide MESH terms for the study
Early versus delayed postoperative radiotherapy for treatment of low‐grade gliomas | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Agents [therapeutic use]; 2. Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; 3. Carboplatin [therapeutic use]; 4. Carcinoma, Non‐Small‐Cell Lung [*drug therapy]; 5. Cisplatin [therapeutic use]; 6. Lung Neoplasms [*drug therapy]; 7. Nausea [chemically induced]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Survival Rate; 11. Treatment Outcome; 12. Vomiting [chemically induced]; | Provide MESH terms for the study
Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Administration, Intravesical; 2. Antibiotics, Antineoplastic [administration & dosage, *therapeutic use]; 3. BCG Vaccine; 4. Carcinoma, Transitional Cell [*drug therapy]; 5. Mitomycin [administration & dosage, *therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Treatment Outcome; 8. Urinary Bladder Neoplasms [*drug therapy]; | Provide MESH terms for the study
Intravesical Bacillus Calmette‐Guérin versus mitomycin C for Ta and T1 bladder cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Brain Neoplasms [*diagnostic imaging, mortality, surgery]; 2. Controlled Before‐After Studies; 3. Glioma [*diagnostic imaging, mortality, surgery]; 4. Magnetic Resonance Imaging [*methods]; 5. Randomized Controlled Trials as Topic; 6. Reoperation; | Provide MESH terms for the study
Interval brain imaging for adults with cerebral glioma | You are a research assistant. Based on the question please provide appropriate answers |
1. Dose‐Response Relationship, Immunologic; 2. Papillomavirus Infections [*prevention & control]; 3. Papillomavirus Vaccines [*administration & dosage]; 4. Randomized Controlled Trials as Topic; 5. Uterine Cervical Neoplasms [prevention & control, virology]; | Provide MESH terms for the study
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males | You are a research assistant. Based on the question please provide appropriate answers |
1. *Cancer Survivors [psychology]; 2. *Patient Satisfaction; 3. Anxiety [rehabilitation]; 4. Continuity of Patient Care; 5. Depression [rehabilitation]; 6. Fatigue [rehabilitation]; 7. Follow‐Up Studies; 8. Neoplasm Recurrence, Local [*diagnosis]; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Follow‐up strategies following completion of primary cancer treatment in adult cancer survivors | You are a research assistant. Based on the question please provide appropriate answers |
1. *Antibiotic Prophylaxis; 2. Breast Neoplasms [*surgery]; 3. Mastectomy; 4. Preoperative Care [methods]; 5. Randomized Controlled Trials as Topic; 6. Surgical Wound Infection [*prevention & control]; 7. Wound Healing; | Provide MESH terms for the study
Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery | You are a research assistant. Based on the question please provide appropriate answers |
1. Colorectal Neoplasms [*drug therapy, *surgery]; 2. Disease‐Free Survival; 3. Follow‐Up Studies; 4. Neoplasm Recurrence, Local; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Follow‐up strategies for patients treated for non‐metastatic colorectal cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Antineoplastic Combined Chemotherapy Protocols; 2. Antineoplastic Agents, Phytogenic [*therapeutic use]; 3. Breast Neoplasms [*drug therapy]; 4. Chemotherapy, Adjuvant; 5. Neoadjuvant Therapy; 6. Paclitaxel [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Taxoids [*therapeutic use]; | Provide MESH terms for the study
Taxanes for adjuvant treatment of early breast cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Prostatic Neoplasms [*radiotherapy]; 2. Quality of Life; 3. *Radiation Dose Hypofractionation; 4. Randomized Controlled Trials as Topic; 5. Treatment Outcome; | Provide MESH terms for the study
Hypofractionation for clinically localized prostate cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Abdomen [surgery]; 2. Anticoagulants [*therapeutic use]; 3. Drug Administration Schedule; 4. Heparin, Low‐Molecular‐Weight [*therapeutic use]; 5. Pelvis [surgery]; 6. Postoperative Complications [epidemiology, prevention & control]; 7. Postoperative Hemorrhage [epidemiology, *prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Venous Thromboembolism [epidemiology, *prevention & control]; | Provide MESH terms for the study
Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Agents [*adverse effects, therapeutic use]; 2. Cognition Disorders [*chemically induced, epidemiology]; 3. Glioma [*therapy]; 4. Radiation Injuries [*complications]; 5. Radiosurgery; 6. Radiotherapy [*adverse effects, methods]; 7. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Long‐term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma | You are a research assistant. Based on the question please provide appropriate answers |
1. *Digestive System Surgical Procedures; 2. *Length of Stay; 3. Enteral Nutrition [*methods]; 4. Postoperative Complications [*prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Time Factors; | Provide MESH terms for the study
Early enteral nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for length of hospital stay and postoperative complications | You are a research assistant. Based on the question please provide appropriate answers |
1. *Anxiety [therapy]; 2. *Caregivers [psychology]; 3. *Depression [therapy]; 4. Health Status; 5. *Neoplasms [nursing]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Psychosocial interventions for informal caregivers of people living with cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Exercise Therapy; 2. Breathing Exercises; 3. Carcinoma, Non‐Small‐Cell Lung [*rehabilitation, surgery]; 4. Exercise Tolerance [*physiology]; 5. Forced Expiratory Volume [physiology]; 6. Health Status; 7. Lung Neoplasms [*rehabilitation, surgery]; 8. Muscle Strength [physiology]; 9. Oxygen Consumption; 10. Postoperative Care [methods]; 11. Quadriceps Muscle [physiology]; 12. Quality of Life; 13. Randomized Controlled Trials as Topic; 14. Resistance Training; 15. Time Factors; | Provide MESH terms for the study
Exercise training undertaken by people within 12 months of lung resection for non‐small cell lung cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Disease Progression; 2. *Prostate-Specific Antigen [therapeutic use]; 3. *Prostatic Neoplasms [drug therapy]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Cystectomy [*methods]; 2. Length of Stay; 3. Nutritional Status; 4. *Perioperative Care; 5. Postoperative Complications [*epidemiology]; 6. Urinary Bladder Neoplasms [*surgery]; 7. Wound Healing; | Provide MESH terms for the study
Perioperative nutrition for the treatment of bladder cancer by radical cystectomy | You are a research assistant. Based on the question please provide appropriate answers |
1. *Administration, Intravesical; 2. Antineoplastic Agents [*administration & dosage, therapeutic use]; 3. Carcinoma [*drug therapy]; 4. Nephroureterectomy; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome; 7. Ureteral Neoplasms [*drug therapy]; | Provide MESH terms for the study
Single‐dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma | You are a research assistant. Based on the question please provide appropriate answers |
1. *Cystectomy [methods]; 2. *Lymph Node Excision; 3. Carcinoma, Transitional Cell [*surgery]; 4. Postoperative Complications; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome; 7. Urinary Bladder Neoplasms [*surgery]; | Provide MESH terms for the study
Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Agents [*adverse effects, therapeutic use]; 2. Carboplatin; 3. Cisplatin; 4. Hearing Loss [*chemically induced, *prevention & control]; 5. Neoplasms [drug therapy]; 6. Organoplatinum Compounds [*adverse effects, therapeutic use]; 7. Oxaliplatin; 8. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Aromatase Inhibitors [*therapeutic use]; 2. Breast Neoplasms [*drug therapy]; 3. Network Meta‐Analysis; 4. Randomized Controlled Trials as Topic; 5. Selective Estrogen Receptor Modulators [*therapeutic use]; | Provide MESH terms for the study
Risk‐reducing medications for primary breast cancer: a network meta‐analysis | You are a research assistant. Based on the question please provide appropriate answers |
1. *Hematopoietic Stem Cell Transplantation; 2. Antibodies, Monoclonal [*therapeutic use]; 3. Consolidation Chemotherapy; 4. Disease‐Free Survival; 5. Immunologic Factors [therapeutic use]; 6. Immunotherapy; 7. Neuroblastoma [immunology, mortality, *therapy]; 8. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation | You are a research assistant. Based on the question please provide appropriate answers |
1. Cystectomy [*methods]; 2. Postoperative Complications [epidemiology]; 3. Quality of Life; 4. Randomized Controlled Trials as Topic; 5. Robotic Surgical Procedures [*methods]; 6. Treatment Outcome; 7. Urinary Bladder Neoplasms [*surgery]; | Provide MESH terms for the study
Robotic versus open radical cystectomy for bladder cancer in adults | You are a research assistant. Based on the question please provide appropriate answers |
1. *Mindfulness; 2. Anxiety [psychology]; 3. Breast Neoplasms [*psychology]; 4. Depression [psychology]; 5. Fatigue [psychology]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Sleep Wake Disorders [psychology]; 9. Stress, Psychological [*therapy]; 10. Time Factors; | Provide MESH terms for the study
Mindfulness‐based stress reduction for women diagnosed with breast cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Mental Health; 2. *Needs Assessment; 3. *Quality of Life; 4. Neoplasms [diagnosis, *psychology]; 5. Non‐Randomized Controlled Trials as Topic; 6. Randomized Controlled Trials as Topic; 7. Stress, Psychological [diagnosis]; | Provide MESH terms for the study
Systematic screening and assessment of psychosocial well‐being and care needs of people with cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Ambulatory Care; 2. Anti-Bacterial Agents [*therapeutic use]; 3. Febrile Neutropenia [chemically induced, *drug therapy, mortality]; 4. Fever [etiology]; 5. *Hospitalization; 6. Length of Stay; 7. Neoplasms [*complications]; 8. Outcome Assessment, Health Care; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Time Factors; 12. Treatment Failure; | Provide MESH terms for the study
Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event | You are a research assistant. Based on the question please provide appropriate answers |
1. Antifibrinolytic Agents [therapeutic use]; 2. Palliative Care [*methods]; 3. Tampons, Surgical; 4. Tranexamic Acid [therapeutic use]; 5. Uterine Cervical Neoplasms [*complications, pathology]; 6. Uterine Hemorrhage [etiology, *therapy]; | Provide MESH terms for the study
Palliative interventions for controlling vaginal bleeding in advanced cervical cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Chronic Disease [*psychology]; 2. Cognitive Behavioral Therapy; 3. Family Relations; 4. Family Therapy; 5. Motivational Interviewing; 6. Parenting [psychology]; 7. Parents [*psychology]; 8. Problem Solving; 9. Psychotherapy [*methods]; 10. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Psychological interventions for parents of children and adolescents with chronic illness | You are a research assistant. Based on the question please provide appropriate answers |
1. Bone Neoplasms [mortality, pathology, *surgery]; 2. Chondrosarcoma [mortality, pathology, *surgery]; 3. Curettage [adverse effects, *methods]; 4. Disease‐Free Survival; 5. Kaplan‐Meier Estimate; 6. Neoplasm Grading; 7. Neoplasm Recurrence, Local; 8. Retrospective Studies; | Provide MESH terms for the study
Intralesional treatment versus wide resection for central low‐grade chondrosarcoma of the long bones | You are a research assistant. Based on the question please provide appropriate answers |
1. *Continuous Positive Airway Pressure [mortality, statistics & numerical data]; 2. *Noninvasive Ventilation [mortality, statistics & numerical data]; 3. Anti‐Bacterial Agents [therapeutic use]; 4. Intensive Care Units [statistics & numerical data]; 5. Length of Stay; 6. Lung Neoplasms [*surgery]; 7. Pneumonectomy [*adverse effects]; 8. Postoperative Complications [epidemiology, *prevention & control]; 9. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Non‐invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients | You are a research assistant. Based on the question please provide appropriate answers |
1. Administration, Intranasal; 2. Antineoplastic Agents [adverse effects]; 3. Gonadotropin-Releasing Hormone [agonists, *analogs & derivatives]; 4. Injections, Intramuscular; 5. Injections, Subcutaneous; 6. Menstruation [*drug effects]; 7. Ovulation [drug effects]; 8. Pregnancy Rate; 9. *Premenopause; 10. Primary Ovarian Insufficiency [chemically induced, *prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Recovery of Function [drug effects]; | Provide MESH terms for the study
Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure in premenopausal women | You are a research assistant. Based on the question please provide appropriate answers |
1. Administration, Oral; 2. Adrenal Cortex Hormones [administration & dosage, adverse effects, *therapeutic use]; 3. Dexamethasone [administration & dosage, adverse effects, *therapeutic use]; 4. Dyspnea [*drug therapy, etiology]; 5. Neoplasms [*complications]; | Provide MESH terms for the study
Systemic corticosteroids for the management of cancer‐related breathlessness (dyspnoea) in adults | You are a research assistant. Based on the question please provide appropriate answers |
1. Anastomosis, Surgical [methods]; 2. Arm; 3. Breast Neoplasms [*radiotherapy, *surgery]; 4. Lymphatic Vessels [radiation effects, *surgery, transplantation]; 5. Lymphedema [etiology, *prevention & control, *surgery]; 6. Postoperative Complications [*prevention & control, *surgery]; 7. Randomized Controlled Trials as Topic; 8. Reproducibility of Results; 9. Venules [*surgery]; | Provide MESH terms for the study
Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment | You are a research assistant. Based on the question please provide appropriate answers |
1. *Radiotherapy, Conformal [adverse effects]; 2. Carcinoma, Hepatocellular [metabolism, mortality, *therapy]; 3. Cause of Death; 4. Chemoembolization, Therapeutic [adverse effects, *methods]; 5. Combined Modality Therapy [adverse effects, methods]; 6. Liver Neoplasms [metabolism, mortality, *therapy]; 7. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults | You are a research assistant. Based on the question please provide appropriate answers |
1. *Autonomic Nervous System; 2. Disease‐Free Survival; 3. Hysterectomy [adverse effects, *methods]; 4. Neoplasm Recurrence, Local; 5. Neoplasm Staging; 6. Organ Sparing Treatments [adverse effects, *methods, mortality]; 7. Pelvis [innervation]; 8. Postoperative Complications [*prevention & control]; 9. Randomized Controlled Trials as Topic; 10. Urinary Bladder [*innervation]; 11. Urination Disorders [etiology, *prevention & control]; 12. Uterine Cervical Neoplasms [pathology, *surgery]; | Provide MESH terms for the study
Nerve‐sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa) | You are a research assistant. Based on the question please provide appropriate answers |
1. *Papillomaviridae; 2. Carcinoma, Squamous Cell [surgery, *therapy, *virology]; 3. Chemoradiotherapy, Adjuvant [*methods, standards]; 4. Laser Therapy [methods]; 5. Microsurgery [methods]; 6. Oropharyngeal Neoplasms [surgery, *therapy, *virology]; 7. Radiotherapy Dosage; 8. Robotic Surgical Procedures; | Provide MESH terms for the study
De‐intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV‐positive oropharyngeal carcinoma | You are a research assistant. Based on the question please provide appropriate answers |
1. *Exercise; 2. *Physical Fitness; 3. Breast Neoplasms [surgery, therapy]; 4. Combined Modality Therapy; 5. Fatigue [prevention & control]; 6. Home Care Services; 7. Muscle Strength; 8. Neoplasms [surgery, *therapy]; 9. Patient Safety; 10. Quality of Life; 11. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Exercise interventions for people undergoing multimodal cancer treatment that includes surgery | You are a research assistant. Based on the question please provide appropriate answers |
1. Angiogenesis Inhibitors [adverse effects, *therapeutic use]; 2. Antibodies, Monoclonal, Humanized [adverse effects, therapeutic use]; 3. Antineoplastic Agents [therapeutic use]; 4. Bevacizumab [therapeutic use]; 5. Brain Neoplasms [blood supply, *drug therapy, mortality]; 6. Camptothecin [analogs & derivatives, therapeutic use]; 7. Dacarbazine [analogs & derivatives, therapeutic use]; 8. Glioblastoma [blood supply, *drug therapy, mortality]; 9. Hypertension [chemically induced]; 10. Irinotecan [therapeutic use]; 11. Lomustine [therapeutic use]; 12. Neoplasm Recurrence, Local [drug therapy]; 13. Neovascularization, Pathologic [*drug therapy, mortality]; 14. Progression-Free Survival; 15. Proteinuria [chemically induced]; 16. Randomized Controlled Trials as Topic; 17. Snake Venoms [therapeutic use]; 18. Temozolomide [therapeutic use]; | Provide MESH terms for the study
Anti‐angiogenic therapy for high‐grade glioma | You are a research assistant. Based on the question please provide appropriate answers |
1. *Time‐to‐Treatment; 2. Antineoplastic Agents [adverse effects, *therapeutic use]; 3. Asymptomatic Diseases [*therapy]; 4. Colonic Neoplasms [*drug therapy, *mortality, pathology]; 5. Confidence Intervals; 6. Diarrhea [chemically induced]; 7. Drug Administration Schedule; 8. Nausea [chemically induced]; 9. Palliative Care [*statistics & numerical data]; 10. Proportional Hazards Models; 11. Randomized Controlled Trials as Topic; 12. Rectal Neoplasms [*drug therapy, *mortality, pathology]; 13. Stomatitis [chemically induced]; 14. Survival Analysis; 15. Vomiting [chemically induced]; | Provide MESH terms for the study
Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Antineoplastic Agents [adverse effects]; 2. Leukopenia [etiology, *therapy]; 3. *Moxibustion; 4. Nausea [etiology, *therapy]; 5. Neoplasms [blood, *drug therapy, *radiotherapy]; 6. Platelet Count; 7. Publication Bias; 8. Quality of Life; 9. Radiotherapy [adverse effects]; 10. Randomized Controlled Trials as Topic; 11. Vomiting [etiology, *therapy]; | Provide MESH terms for the study
Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Blood Loss, Surgical [statistics & numerical data]; 2. Disease‐Free Survival; 3. Endometrial Neoplasms [mortality, pathology, *surgery]; 4. Hysterectomy [adverse effects, *methods, mortality]; 5. Laparoscopy [adverse effects, *methods, mortality]; 6. Laparotomy [adverse effects, *methods, mortality]; 7. Length of Stay; 8. Neoplasm Recurrence, Local; 9. Postoperative Complications; 10. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Laparoscopy versus laparotomy for the management of early stage endometrial cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Chemoradiotherapy; 2. Disease Progression; 3. Lymph Nodes [pathology]; 4. Lymphatic Irradiation [adverse effects, *methods]; 5. Lymphatic Metastasis [pathology, *radiotherapy]; 6. Neoplasm Recurrence, Local [pathology, radiotherapy]; 7. Pelvis; 8. Progression‐Free Survival; 9. Randomized Controlled Trials as Topic; 10. Uterine Cervical Neoplasms [drug therapy, mortality, pathology, *radiotherapy]; | Provide MESH terms for the study
Extended‐field radiotherapy for locally advanced cervical cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Androgen Antagonists [*therapeutic use]; 2. Antineoplastic Agents, Hormonal [adverse effects, *therapeutic use]; 3. Disease Progression; 4. Prostatic Neoplasms [*drug therapy, mortality, pathology]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Taxoids [adverse effects, *therapeutic use]; 8. Withholding Treatment [statistics & numerical data]; | Provide MESH terms for the study
Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Antibodies, Monoclonal [adverse effects, *therapeutic use]; 2. Antibodies, Monoclonal, Humanized [adverse effects, therapeutic use]; 3. Antineoplastic Agents [adverse effects, *therapeutic use]; 4. Deoxycytidine [*analogs & derivatives, therapeutic use]; 5. ErbB Receptors [*antagonists & inhibitors]; 6. Erlotinib Hydrochloride [adverse effects, therapeutic use]; 7. Neoplasm Recurrence, Local [drug therapy]; 8. Ovarian Neoplasms [*drug therapy, mortality]; 9. Piperidines [adverse effects, therapeutic use]; 10. Progression‐Free Survival; 11. Quality of Life; 12. Quinazolines [adverse effects, therapeutic use]; 13. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Epidermal growth factor receptor blockers for the treatment of ovarian cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Accidental Falls [*prevention & control]; 2. *Cancer Survivors; 3. *Exercise; 4. *Muscle Strength; 5. Neoplasms [*complications]; 6. Postural Balance; 7. Randomized Controlled Trials as Topic; 8. Range of Motion, Articular; | Provide MESH terms for the study
Exercise for reducing falls in people living with and beyond cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Chemoradiotherapy; 2. Hysterectomy [*methods]; 3. Neoplasm Staging; 4. Non‐Randomized Controlled Trials as Topic; 5. Uterine Cervical Neoplasms [pathology, *therapy]; | Provide MESH terms for the study
Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage IB2 cervical cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. Anal Canal; 2. Dose Fractionation, Radiation; 3. Neoplasm Recurrence, Local [prevention & control]; 4. Organ Sparing Treatments; 5. Postoperative Complications [etiology]; 6. Preoperative Care; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Rectal Neoplasms [mortality, pathology, *radiotherapy, *surgery]; 10. Rectum [surgery]; | Provide MESH terms for the study
Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma | You are a research assistant. Based on the question please provide appropriate answers |
1. Antiemetics [adverse effects, *therapeutic use]; 2. Antineoplastic Agents [adverse effects]; 3. Benzodiazepines [adverse effects, *therapeutic use]; 4. Chemoradiotherapy [adverse effects]; 5. Dexamethasone [therapeutic use]; 6. Disorders of Excessive Somnolence [chemically induced]; 7. Fatigue; 8. Metoclopramide [therapeutic use]; 9. Nausea [*drug therapy, etiology, prevention & control]; 10. Neoplasms [*complications]; 11. Olanzapine; 12. Quality of Life; 13. Randomized Controlled Trials as Topic; 14. Vomiting [*drug therapy, etiology, prevention & control]; | Provide MESH terms for the study
Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults | You are a research assistant. Based on the question please provide appropriate answers |
1. Diarrhea [complications, prevention & control, *therapy]; 2. Neoplasms [*drug therapy, *radiotherapy]; 3. Placebos [therapeutic use]; 4. Probiotics [*therapeutic use]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Food, Fortified [adverse effects]; 2. Arginine [administration & dosage]; 3. Cause of Death; 4. Fatty Acids [administration & dosage]; 5. Fistula [epidemiology]; 6. Glutamine [administration & dosage]; 7. Head and Neck Neoplasms [complications, *surgery]; 8. Length of Stay; 9. Malnutrition [etiology, *therapy]; 10. Postoperative Complications [epidemiology, *prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Surgical Wound Infection [epidemiology]; | Provide MESH terms for the study
Immunonutrition for patients undergoing surgery for head and neck cancer | You are a research assistant. Based on the question please provide appropriate answers |
1. *Genes, BRCA1; 2. *Genes, BRCA2; 3. Breast Neoplasms [mortality, *prevention & control]; 4. Heterozygote; 5. Mastectomy [*methods]; 6. Mutation [*genetics]; 7. Ovarian Neoplasms [mortality, *prevention & control]; 8. Quality of Life; 9. Salpingo‐oophorectomy [adverse effects, mortality, *statistics & numerical data]; | Provide MESH terms for the study
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations | You are a research assistant. Based on the question please provide appropriate answers |
1. Brain Neoplasms [mortality, *radiotherapy, *secondary, *surgery]; 2. Combined Modality Therapy [methods, mortality]; 3. Cranial Irradiation [methods, mortality]; 4. Progression‐Free Survival; 5. Radiosurgery [adverse effects, *methods, mortality]; 6. Randomized Controlled Trials as Topic; | Provide MESH terms for the study
Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis | You are a research assistant. Based on the question please provide appropriate answers |
1. *Clinical Competence; 2. *Virtual Reality; 3. Endoscopy, Gastrointestinal [*education]; 4. Health Personnel [*education]; 5. Randomized Controlled Trials as Topic; 6. Simulation Training [*methods]; | Provide MESH terms for the study
Virtual reality simulation training for health professions trainees in gastrointestinal endoscopy | You are a research assistant. Based on the question please provide appropriate answers |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.